NV-VERIMATRIX
NAB Show 2019 (Booth #SU3110) – Verimatrix , an Inside Secure (Euronext Paris – INSD) company, today announced API integration between its Verimatrix Video Content Authority System (VCAS) Ultra™ and AWS Elemental MediaConnect. The API integration provides conditional access (CA) and rights management applied between the content ingest and distribution workflows to video service providers.
As content providers and video service operators move content delivery workflows to the cloud, they need a reliable and efficient way to upload and transfer live streams. The VCAS Ultra API integration with AWS Elemental MediaConnect is designed to fulfill two main use cases – securing distribution workflows to downstream operators and enforcing the entitlements that ensure authorized operators have access to the right live streams.
AWS Media Services make it fast and easy to prepare, process, and deliver broadcast and multiscreen video from AWS. AWS Elemental MediaConnect is a high-quality transport service for live video that allows users to build mission-critical live video transport workflows in a fraction of the time and cost of satellite or fiber, with broadcast-grade monitoring and management.
The API integration features VCAS Ultra deployed in the Verimatrix Secure Cloud™ , which is a comprehensive software-as-a-service (SaaS) platform leveraging AWS so customers can eliminate the need to install, configure and manage physical servers to operate VCAS Ultra services.
“VCAS Ultra is a proven and widely adopted security solution for premium video services, and our API integration with AWS Elemental MediaConnect offers value-added flexibility and options for live video distribution,” said Petr Peterka, CTO of Verimatrix. “The ability to secure, authenticate, and enforce distribution rights of live broadcast content in an automatic fashion is another example of a leading-edge cloud workflow that offers a compelling alternative to satellite or fiber distribution.”
In addition to the standalone importance of secure cloud-based live video distribution via AWS Elemental MediaConnect, this API integration has the potential to further expand deployment models and value proposition of connected content distribution workflows that streamline end-to-end delivery and automate video analytics reporting between content providers and video service operators.
For more information on the benefits of secure cloud-based video delivery, visit us at NAB 2019, booth # SU3110 .
About Verimatrix
Verimatrix specializes in enhancing and securing revenue for connected devices and IP-based services around the world. Recognizing the need to improve digital exchange between content providers, video service operators, and subscribers, Verimatrix is focused on enhancing the connected content distribution workflow by leveraging its award-winning VCAS™ security and Verspective® Analytics solutions, and unmatched partner ecosystem, to reduce the costs and complexities associated with legacy distribution workflows. To learn more, visit www.verimatrix.com , our Pay TV Views blog and follow us @verimatrixinc , Facebook and LinkedIn to join the conversation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190405005374/en/
Contact:
Kelly Foster, Verimatrix +1 619-846-8229 kfoster@verimatrix.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom